— Know what they know.
Not Investment Advice

FWBI NASDAQ

First Wave BioPharma, Inc.
1W: -15.2% 1M: -26.9% 3M: -56.3% 1Y: -94.1% 3Y: -100.0% 5Y: -100.0%
$2.96
Last traded 2024-06-14 — delisted
NASDAQ · Healthcare · Biotechnology · $6.0M mcap · 2M float · 3.52% daily turnover

Balance Sheet Trends

Total Assets
$85M +1140.8% ▲
5Y CAGR: +57.2%
Total Liabilities
$28M +741.6% ▲
5Y CAGR: +45.1%
Shareholders Equity
-$4M -207.6% ▼
Cash & Investments
$163K -95.6% ▼
5Y CAGR: -1.4%
Total Debt
$141K -83.0% ▼
5Y CAGR: -38.6%
Net Debt
-$23K +99.2% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2020FY2021FY2022FY2023FY2024
— Assets —
Cash$6M$8M$1M$4M$163K
Short-Term Investments$0$0$0$0$0
Cash & ST Investments$6M$8M$1M$4M$163K
Net Receivables$551K$0$93K$0$0
Inventory$0$0$0$0$0
Other Current Assets$1M$1M$2M$1M$83M
Total Current Assets$8M$9M$3M$5M$83M
Property, Plant & Equip.$93K$409K$303K$210K$127K
Goodwill & Intangibles$5M$2M$2M$2M$2M
Long-Term Investments$0$0$22K$22K$0
Other Non-Current Assets$28K$44K$40K$11K$120K
Total Non-Current Assets$5M$2M$2M$2M$2M
Total Assets$13M$12M$5M$7M$85M
— Liabilities —
Accounts Payable$2M$3M$720K$554K$3M
Short-Term Debt$610K$719K$670K$680K$82K
Deferred Revenue$0$884K$0$1M$0
Other Current Liabilities$13M$8M$1M$830K$25M
Total Current Liabilities$16M$12M$2M$3M$28M
Long-Term Debt$19K$311K$214K$147K$59K
Other Non-Current Liab.$0$7M$0$0$0
Total Non-Current Liabilities$19K$7M$214K$147K$59K
Total Liabilities$16M$20M$3M$3M$28M
— Equity —
Common Stock$3K$1K$100$156$475
Retained Earnings-$95M-$154M-$169M-$184M-$202M
Accumulated OCI-$1M-$1M$0$0$0
Total Stockholders Equity-$3M-$8M$3M$4M-$4M
Total Liabilities & Equity$13M$12M$5M$7M$85M
— Key Metrics —
Total Debt$629K$1M$884K$827K$141K
Net Debt-$5M-$7M-$479K-$3M-$23K
Total Investments$0$0$22K$22K$0

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms